Arcutis Biotherapeutics, Inc., a biopharmaceutical company, has filed an amendment to its tender offer statement with the U.S. Securities and Exchange Commission (SEC) on January 24, 2024. The amendment pertains to the company's offer to exchange certain outstanding eligible stock options for a lesser number of new restricted stock units for employees and consultants, initially announced on January 16, 2024. The offer involves up to 5,108,908 shares of common stock. The amendment includes changes to the conditions of the offer, particularly addressing circumstances that could affect the offer's completion, such as significant market price changes or index declines. Additionally, the amendment outlines the process for public announcements in the event of an extension, termination, or further amendment to the offer. The company's General Counsel and Corporate Secretary, Mas Matsuda, has certified the accuracy of the information provided in the amendment.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, has filed an amendment to its tender offer statement with the U.S. Securities and Exchange Commission (SEC) on January 24, 2024. The amendment pertains to the company's offer to exchange certain outstanding eligible stock options for a lesser number of new restricted stock units for employees and consultants, initially announced on January 16, 2024. The offer involves up to 5,108,908 shares of common stock. The amendment includes changes to the conditions of the offer, particularly addressing circumstances that could affect the offer's completion, such as significant market price changes or index declines. Additionally, the amendment outlines the process for public announcements in the event of an extension, termination, or further amendment to the offer. The company's General Counsel and Corporate Secretary, Mas Matsuda, has certified the accuracy of the information provided in the amendment.